Seeking Alpha

More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding...

More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding eteplirsen in the PR. The company says it is "encouraged" by its correspondence with the FDA and is "finalizing" its response to requests for further information (I, II). A $6.7M decrease in government contract revenue is blamed for the higher (Y/Y) operating loss. Operating expenses were higher as the company expands its Duchenne muscular dystrophy program. Shares +1.24% premarket.

Check out Seeking Alpha’s new Earnings Center »

Comments (2)
  • simp08801
    , contributor
    Comments (6) | Send Message
     
    "Nothing particularly groundbreaking"? The CEO stated he expects to meet with FDA on new dmd data submission by end of Q2. This meeting was assumed to occur as late as Q4. Schedule on FDA final determination of filing of AA application appears materially condensed based on CEO comments.
    9 May 2013, 09:03 AM Reply Like
  • whaddyamean?
    , contributor
    Comments (514) | Send Message
     
    "Nothing particularly groundbreaking" = windbreaking
    9 May 2013, 09:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs